The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 1
  • Milligan, Claire Lisa
    Pharmaceutical Clinician born in November 1971
    Individual (3 offsprings)
    Officer
    2016-01-15 ~ now
    OF - Director → CIF 0
    Mrs Claire Lisa Milligan
    Born in November 1971
    Individual (3 offsprings)
    Person with significant control
    2017-01-14 ~ now
    PE - Ownership of shares – 75% or more → CIF 0
parent relation
Company in focus

CLAIRE DAVIES PHARMA CONSULTING LIMITED

Standard Industrial Classification
70229 - Management Consultancy Activities Other Than Financial Management
Brief company account
Par Value of Share
Class 1 ordinary share
12023-02-01 ~ 2024-01-31
Total Inventories
7,650 GBP2024-01-31
12,210 GBP2023-01-31
Debtors
974 GBP2024-01-31
4,428 GBP2023-01-31
Cash at bank and in hand
126,441 GBP2024-01-31
148,906 GBP2023-01-31
Current Assets
135,065 GBP2024-01-31
165,544 GBP2023-01-31
Creditors
Current
7,832 GBP2024-01-31
16,173 GBP2023-01-31
Net Current Assets/Liabilities
127,233 GBP2024-01-31
149,371 GBP2023-01-31
Total Assets Less Current Liabilities
184,792 GBP2024-01-31
218,604 GBP2023-01-31
Net Assets/Liabilities
175,933 GBP2024-01-31
208,582 GBP2023-01-31
Equity
Called up share capital
100 GBP2024-01-31
100 GBP2023-01-31
Equity
175,933 GBP2024-01-31
208,582 GBP2023-01-31
Average Number of Employees
12023-02-01 ~ 2024-01-31
12022-02-01 ~ 2023-01-31
Property, Plant & Equipment - Gross Cost
Improvements to leasehold property
55,270 GBP2024-01-31
55,270 GBP2023-01-31
Plant and equipment
499 GBP2024-01-31
499 GBP2023-01-31
Furniture and fittings
6,297 GBP2024-01-31
6,297 GBP2023-01-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Improvements to leasehold property
44,472 GBP2024-01-31
38,945 GBP2023-01-31
Plant and equipment
134 GBP2024-01-31
69 GBP2023-01-31
Furniture and fittings
4,591 GBP2024-01-31
4,290 GBP2023-01-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Improvements to leasehold property
5,527 GBP2023-02-01 ~ 2024-01-31
Plant and equipment
65 GBP2023-02-01 ~ 2024-01-31
Furniture and fittings
301 GBP2023-02-01 ~ 2024-01-31
Property, Plant & Equipment
Improvements to leasehold property
10,798 GBP2024-01-31
16,325 GBP2023-01-31
Plant and equipment
365 GBP2024-01-31
430 GBP2023-01-31
Furniture and fittings
1,706 GBP2024-01-31
2,007 GBP2023-01-31
Property, Plant & Equipment - Gross Cost
Motor vehicles
56,090 GBP2024-01-31
56,090 GBP2023-01-31
Computers
3,584 GBP2024-01-31
1,476 GBP2023-01-31
Property, Plant & Equipment - Gross Cost
121,740 GBP2024-01-31
119,632 GBP2023-01-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Motor vehicles
13,214 GBP2024-01-31
5,647 GBP2023-01-31
Computers
1,770 GBP2024-01-31
1,445 GBP2023-01-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
64,181 GBP2024-01-31
50,396 GBP2023-01-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Motor vehicles
7,567 GBP2023-02-01 ~ 2024-01-31
Computers
325 GBP2023-02-01 ~ 2024-01-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
13,785 GBP2023-02-01 ~ 2024-01-31
Property, Plant & Equipment
Motor vehicles
42,876 GBP2024-01-31
50,443 GBP2023-01-31
Computers
1,814 GBP2024-01-31
31 GBP2023-01-31
Property, Plant & Equipment
57,559 GBP2024-01-31
69,236 GBP2023-01-31
Value of work in progress
7,650 GBP2024-01-31
12,210 GBP2023-01-31
Trade Debtors/Trade Receivables
Current
4,428 GBP2023-01-31
Debtors
Current, Amounts falling due within one year
974 GBP2024-01-31
4,428 GBP2023-01-31
Trade Creditors/Trade Payables
Current
90 GBP2024-01-31
Corporation Tax Payable
Current
3,246 GBP2024-01-31
9,012 GBP2023-01-31
Other Taxation & Social Security Payable
Current
162 GBP2024-01-31
319 GBP2023-01-31
Other Creditors
Current
245 GBP2023-01-31
Accrued Liabilities
Current
790 GBP2024-01-31
720 GBP2023-01-31
Amounts set aside to cover potential liabilities or losses
Deferred taxation
8,859 GBP2024-01-31
10,022 GBP2023-01-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
100 shares2024-01-31
  • CLAIRE DAVIES PHARMA CONSULTING LIMITED
    Info
    Registered number 09953150
    45 Queen Street, Deal, Kent CT14 6EY
    Private Limited Company incorporated on 2016-01-15 (9 years 5 months). The company status is Active.
    The last date of confirmation statement was made at 2025-01-14
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.